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ABSTRACT 
Dyskeratosis congenita is a highly pleotropic genetic disorder. This heterogeneity can lead to 
difficulties in making an accurate diagnosis and delays in appropriate management. The aim of this 
study was to determine the underlying genetic basis in patients presenting with features of 
dyskeratosis congenita and who were negative for mutations in the classical dyskeratosis congenita 
genes. By whole exome and targeted sequencing, we identified biallelic variants in genes that are not 
associated with dyskeratosis congenita in 17 individuals from 12 families. Specifically these were 
homozygous variants in USB1 (eight families), homozygous missense variants in GRHL2 (two 
families) and identical compound heterozygous variants in LIG4 (two families). All patients had 
multiple somatic features of dyskeratosis congenita but not the characteristic short telomeres. Our 
case series shows that biallelic variants in USB1, LIG4 and GRHL2, the genes mutated in 
poikiloderma with neutropenia, LIG4/Dubowitz syndrome and the recently recognised ectodermal 
dysplasia/short stature syndrome, respectively, cause features that overlap with dyskeratosis 
congenita. Strikingly these genes also overlap in their biological function with the known dyskeratosis 
congenita genes that are implicated in telomere maintenance and DNA repair pathways. Collectively 
these observations demonstrate the marked overlap of dyskeratosis congenita with four other genetic 
syndromes confounding accurate diagnosis and subsequent management. This has important 
implications for establishing a genetic diagnosis when a new patient presents in the clinic. Patients 
with clinical features of dyskeratosis congenita need to have genetic analysis of USB1, LIG4 and 
GRHL2 in addition to the classical dyskeratosis congenita genes and telomere length measurements.  
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INTRODUCTION 
Dyskeratosis congenita (DC) is a highly heterogeneous genetic and clinical syndrome. The classical 
presentation of DC is characterized by the mucocutaneous triad of abnormal skin pigmentation 
(hyper/hypopigmentation with atrophy and telangiectasia, termed poikiloderma), oral leukoplakia and 
nail dystrophy. Individuals with DC frequently develop bone marrow (BM) failure, are at a high risk 
of developing cancer and can develop disease features in virtually every system in the body. 
Pathologically DC is characterized by selective exhaustion of highly proliferative cells1 that have 
critically short telomeres and exhibit an abnormal DNA damage response.2 
The Dyskeratosis Congenita Registry (DCR, London) is a collection of patients that have a clinical 
diagnosis of DC or an overlapping phenotype as defined by Dokal et al.3 The diagnostic inclusion 
criteria are: 
(1) All three mucocutaneous features (abnormal skin pigmentation, nail dystrophy and oral 
leukoplakia). 
(2) One mucocutaneous feature plus BM failure and two other somatic features of DC.  
(3) Aplastic anaemia (AA), myelodysplastic syndrome (MDS) or idiopathic pulmonary fibrosis 
(IPF) associated with a pathogenic telomerase variant. 
(4) Hoyeraal Hreidarsson syndrome (HHS, growth retardation, developmental delay, 
microcephaly, cerebellar hypoplasia, BM failure and immunodeficiency). 
(5)  Two or more features seen in DC plus very short telomeres (<1st centile).   
Based on these criteria the phenotype of DC is highly variable. Furthermore, not all physical 
malformations are present at the point of diagnosis, with many additional features developing with 
age or, in the case of severe disease, death may occur before more typical clinical presentations 
become apparent. 
To date pathogenic mutations have been identified in 11 genes that cause DC according to the criteria 
above: dyskeratosis congenita 1, dyskerin (DKC1), telomerase RNA component (TERC), telomerase 
reverse transcriptase (TERT), NOP10 ribonucleoprotein (NOP10), NHP2 ribonucleoprotein (NHP2), 
TERF1 (TRF1)-interacting nuclear factor 2 (TINF2), WD repeat containing, antisense to TP53 
(WRAP53, also known as TCAB1), CST telomere maintenance complex component 1 (CTC1), 
regulator of telomere elongation helicase 1 (RTEL1), adrenocortical dysplasia homolog (mouse) 
(ACD) and poly(A)-specific ribonuclease (PARN). DKC1, TERC, TERT, NOP10 and NHP2 all 
encode components of the telomerase complex which is involved in telomere elongation. TINF2 and 
ACD encode components of the shelterin complex which is involved in telomere protection. CTC1 
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encodes a member of the CST complex which facilitates recruitment and docking of telomerase on to 
the telomere. WRAP53 is involved in telomerase trafficking and RTEL1 is involved in telomere 
replication, and DNA replication and repair. 3-7 The final gene, PARN, is not exclusively involved in 
telomere biology but is mutated in a small number of cases of DC, and is an exoribonuclease involved 
in the control of mRNA stability and the maturation of TERC snoRNA.8-10 As the majority of DC 
genes are involved in telomere biology and DC patients usually have short telomeres, this has led to 
DC being classed as a telomeropathy.11 However these mutations do not explain all the cases that are 
present in the DCR (Data from the DCR, London, April 2016). 
The advent of next generation sequencing, particularly whole exome sequencing (WES), has become 
an invaluable tool for determining the causal variant(s) underlying a specific disease. By sequencing 
all the coding regions and comparing variants in many individuals with an overlapping phenotype it is 
possible to elucidate potential disease genes in a way that would not have been possible five years 
ago.12 This can give the clinical diagnosis a genetic basis. The main problem in obtaining a definitive 
clinical diagnosis is the degree of phenotypic overlap that exists between many different diseases. The 
diagnosis, in many cases, depends on the interpretation of the initial clinician and this is often 
dependent on their speciality. Although subsequent opinions may be sought, the preliminary diagnosis 
tends to remain with the patient until proven otherwise. An accurate genetic diagnosis can aid clinical 
diagnosis and subsequent patient management. This has the potential to suggest alternative treatment 
avenues that may not have been considered and also aid the selection of healthy sibling donors for 
hematopoietic stem cell transplantation, should this become necessary.  
 
Here we report 12 families with an initial diagnosis of DC who were found to have biallelic variants 
in one of three genes linked to a disease distinct from DC. The genes identified were USB1 (U6 
snRNA biogenesis 1) associated with poikiloderma with neutropenia (PN), GRHL2 (grainyhead like 
transcription factor 2) which is associated with ectodermal dysplasia/short stature syndrome (ECTDS) 
and LIG4 (Ligase IV, DNA, ATP-dependent) which is predominantly associated with LIG4 syndrome 
and occasionally Dubowitz syndrome. The key presenting features of PN are poikiloderma with non-
cycling neutropenia, recurrent infections, short stature and nail abnormalities13. The typical clinical 
features associated with ECTDS are short stature, nail dystrophy, abnormal oral pigmentation, and 
keratoderma and hyperkeratosis of the hands and feet14. LIG4 syndrome is characterized by immune 
deficiency and developmental and growth delay15. Patients can also display unusual facial features, 
microcephaly, pancytopenia and various skin abnormalities. Dubowitz syndrome is characterised by 
growth failure/short stature, characteristic facial features, microcephaly, mild mental retardation and 
eczema16. All of these disorders have a high degree of phenotypic overlap with DC, thus leading to 
difficulties in making an accurate clinical diagnosis. The identification of biallelic USB1, GRHL2 and 
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LIG4 mutations in 12 different families, initially diagnosed to have DC, therefore demonstrate the 
marked phenotypic overlap of ‘classical DC’ with four other genetic syndromes.  
 
METHODS 
Patient samples 
Exome capture or targeted gene screening was performed on a series of genetically uncharacterized 
index cases in the Dyskeratosis Congenita Registry (held at Barts and The London). Presenting 
features included some/all of the classic mucocutaneous abnormalities (abnormal skin pigmentation, 
nail dystrophy, leukoplakia), with or without bone marrow failure. Peripheral-blood samples were 
obtained with written consent under the approval of our local research ethics committee (London – 
City and East). Genomic DNA was extracted from these peripheral blood samples for use in all the 
subsequent analyses (Puregene, Qiagen). 
Telomere length measurement 
Telomere lengths were measured using the MMqPCR method (modified from Cawthon17), on a 
LightCycler 480 real time thermocycler (Roche). Briefly, in each well, amplification of telomeric 
DNA (T) and a single copy gene (S) were quantified against standard curves obtained from dilution of 
a reference DNA sample. The T/S ratio, obtained in triplicate for each sample, is proportional to the 
telomere length. This ratio was normalized to the T/S ratio of a second reference sample that was run 
on every plate to give a relative T/S ratio.  
Whole exome sequencing (WES) 
50ng genomic DNA was subjected to library preparation and exome capture using the Nextera Rapid 
Capture Exome kit (Illumina). Sequencing was performed using the Illumina HiSeq 2000 system and 
100bp paired end reads were generated and the data processed through the Illumina pipeline. Variants 
were called as described previously.8 All relevant variants were confirmed by Sanger sequencing.  
Targeted gene screening 
We designed an NGS assay covering the coding regions and some 5’UTR’s from 31 genes associated 
with genetic bone marrow failure syndromes (Supplementary Table 1). We used the Illumina TruSeq 
custom amplicon kit for library preparation and capture according to manufacturer’s instructions. The 
resultant targeted fragments were indexed by dual barcodes and then sequenced on the Illumina 
MiSeq platform. Read alignment was performed automatically using the online MSR: TruSeq 
amplicon software. Annotation of the variants was performed using ANNOVAR.  
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Variant filtering 
Exome data from our patients were jointly called with 2500 WES internal control samples (UCL-ex 
consortia) with unrelated conditions to minimise artificial batch effects. Where there was a family 
history we assumed an autosomal recessive mode of inheritance as all parents were reportedly 
asymptomatic. Filtering was performed using the following criteria: All variants had to pass the 
Illumina filter, have a read depth of >10X, be present in the general population at a frequency of 
<0.0002 as reported on Exome Aggregation Consortium database, ExAC 
(www.exac.broadinstitute.org), 1000 genome project (www.1000genomes.org) and from the UCL-ex 
consortia. Variants that were predicted to be tolerated and benign by SIFT (http://sift.jcvi.org/) and 
Polyphen (http://genetics.bwh.harvard.edu/pph2/) were then removed from further analysis. All 
relevant variants were confirmed by Sanger sequencing. 
 
RESULTS 
Telomere length analysis 
It has been well established that in the majority of patients with “classical” DC who have mutations in 
components of the telomere maintenance pathway have short telomeres, usually below the 1st 
centile.18, 19 In fact this measure is often used as a diagnostic screening tool to perform a differential 
diagnosis of DC from other bone marrow failure syndromes such as Fanconi anemia. 20 Telomere 
lengths were therefore measured in our patients by MMqPCR and this was used as an indicator of 
whether we could be looking for a mutation in a known telomere biology related gene or not. As none 
of the patients reported in this study had short telomeres when compared with controls (Figure 1), this 
suggested that we were looking for mutations outside the spectrum of those usually associated with 
DC but they could still be associated with other bone marrow failure diseases or else have a 
previously unidentified association to another pathology. 
Identification of causal genetic variants 
Analysis of our data has identified significant biallelic variants in three genes as detailed below. Five 
families underwent WES (Families 4, 9-12) and the remaining underwent targeted sequencing either 
using a 31 bone marrow failure disease gene panel (Supplementary Table 1) or direct sequencing. 
USB1 (U6 snRNA biogenesis 1) 
Biallelic USB1 mutations have been previously described in patients with DC and the overlapping 
disease poikiloderma with neutropenia (PN).21, 22 Since our previous publication,21 we have identified 
homozygous USB1 variants in an additional eight families with features of DC. In seven of the eight 
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families, the variant was identified by targeted sequencing and the remaining family (two cases) 
underwent WES. The only variant that was homozygous and shared by both affected siblings was in 
USB1 so this was deemed to be causal. Five out of the eight index cases had the previously 
documented recurring homozygous variant c.531delA, p.His179MetfsTer8613 (Figure 2A) which is 
not described on ExAc, (accessed April 2016). The sixth index case was found to have the 
homozygous variant c.673C>T, p.Gln225Ter (Figure 2B), which has been reported previously as part 
of a compound heterozygote.23 The remaining two families (Family 7 and Family 8) have the same 
homozygous missense mutation c.623A>G, p.His208Arg (Figure 2C). This is the first report of a 
homozygous missense being associated with disease in USB1 as to date all 19 disease-causing 
variants reported in USB1 are predicted to be loss of function (splicing, nonsense or frame shift).13 
Segregation analysis confirmed an autosomal recessive mode of inheritance and homozygous variants 
were confirmed in an additional four affected siblings within these families (Figure 2A). In silico 
analysis of mutations on USB1 crystal structure (PDB id: 4W7H, Figure 2D) revealed that both 
p.His179MetfsTer86 and p.Gln225Ter truncates several α-helices and β-sheets in USB1 (Figure 2E 
and 2F). Furthermore the homozygous missense change p.His208Arg identified in families 7 and 8 
affects the highly conserved histidine residue H208, (Supplementary Figure 1 and Figure 2G and 2H). 
This change is predicted to be probably damaging by polyphen2 
(http://genetics.bwh.harvard.edu/pph2/; HumVar score 1.0) and disease causing by Mutation taster 
(http://www.mutationtaster.org). This H208 residue is implicated in the catalytic mechanism of USB1, 
where it facilitates displacement of uridine nucleoside on RNA substrate to stabilise U6 small nuclear 
RNA, which in turn plays a critical role in RNA splicing.24 
Table 1 summarises the clinical presentation of these families and the similarity between the clinical 
presentation of DC and PN is further highlighted in Figure 3. The degree of overlap between the 
reticular pigmentation observed on the legs (Figure 3A-C), nail dystrophy of the toes (Figure 3D-F) is 
marked. Similar pigmentation is seen on the trunk (Figure 3G and 3H) and nail dystrophy and 
blistering is shown on the hands (Figure 3I). In addition to highlighting the similarity between the 
cutaneous presentation of DC and PN, panels B, C, E, F and H, I also emphasise the difference in 
presentation that can be caused by mutations within the same gene. The blood results detailed in Table 
1 show that although there is neutropenia in all the patients, the overall blood pathology is more 
global rather than being restricted to just one lineage. This investigation has expanded the repertoire 
of USB1 variants identified to date, by adding a recurrent novel homozygous missense variant.  
 
GRHL2 (grainyhead like transcription factor 2) 
The index case from both families 9 and 1025 underwent WES, and as both families were 
consanguineous, we assumed an autosomal recessive mode of inheritance. Using the filtering 
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approach described, it was noted that both families had homozygous non synonymous variants in the 
gene GRHL2 c.1445T>A p.Ile482Lys in Family 9 and c.1213C>A p.Pro405Thr in Family 10 (other 
homozygous calls that fulfilled the filtering criteria are detailed in Supplementary Table 2). 
Segregation analysis confirmed that both variants were inherited in an autosomal recessive manner 
(Figure 4A). Both of these single base substitutions affect highly conserved nucleotides 
(Supplementary Figure 2). As neither variant is reported on ExAc (accessed April 2016) and both 
variants are predicted by polyphen2 to be probably damaging (HumVar scores p.P405T - 0.995 and 
p.I482K - 0.917) and disease causing by Mutation Taster, GRHL2 is the disease causing gene in these 
two families. GRHL2 is a member of a highly conserved family of transcription factors that are 
essential for epithelial development. At the molecular level, the GRHL transcription factors regulate 
the expression of proteins involved in cell proliferation, differentiation, adhesion and polarity. These 
factors adopt a DNA-binding immunoglobulin fold homologous to the DNA-binding domain of key 
tumour suppressor p53.26 Recently Petrof and colleagues described homozygous mutations in GRHL2 
in two families with ectodermal dysplasia/short stature syndrome (ECTDS)14. One of these was 
p.Ile482Lys, which is the same variant as identified in Family 9. All the variants described by us and 
Petrof et al., affect the DNA binding domain of the protein (Figure 4A). Phenotypically there are 
many shared features between our two families (Families 9 and 10) and the ECTDS families reported 
in the literature (Table 2). Another recent study27 examined the role of GRHL2 in the developing 
kidney and clarified the involvement of GRHL2 in a network that controls the development of lumen 
expansion and barrier formation in renal epithelia, which may explain the previously reported renal 
agenesis seen in Family 10.25 This suggests that homozygous variants in the gene GRHL2, previously 
linked to ECTDS, are disease-causing in these two families.  
 
LIG4 (Ligase IV, DNA, ATP-dependent) 
Analysis of exome data from the index cases of Families 11 and 12 failed to reveal any homozygous 
variants that passed the filtering strategy. However, a biallelic analysis showed that they both shared 
the same compound heterozygous variants in LIG4 namely c.2440C>T, p.Arg814Ter and 
c.1270_1274 delAAAAG, p.Lys424ArgfsTer20 (Figure 4B, other biallelic calls are listed in 
Supplementary Table 2). Although both variants observed in Families 11 and 12 are reported on ExAc 
at very low frequency (0.000082 and 0.00014, respectively) in the heterozygous state, the likelihood 
of them occurring together (as is the case here) by chance is 2.4x10-8. LIG4 is involved in DNA non-
homologous end joining and V(D)J recombination.28 Biallelic mutations in LIG4 are rare with only 28 
cases being reported to date in the literature,29 and are usually associated with LIG4 syndrome and 
more recently in Dubowitz syndrome (DS).16 Both LIG4 syndrome and DS belong to a group of 
disorders that are associated with impaired DNA damage response mechanisms.28 LIG4 syndrome is a 
hereditary disorder associated with impaired DNA double-strand break repair mechanisms. It is 
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characterized by growth restriction, developmental delay, microcephaly, facial dysmorphism, 
pancytopenia, variable immune deficiency and an increased predisposition to leukemia. DS is a rare 
multiple congenital syndrome characterized by cognitive delay, growth failure, microcephaly, 
distinctive facial dysmorphism, immune defects, pancytopenia, hematological malignancy and 
neuroblastoma. The degree of clinical overlap between LIG4 syndrome, DS and our two patients is 
marked (Table 2). Furthermore the fact that both of the variants in LIG4 described here have been 
previously documented to be pathogenic and have been shown to occur in the same combination30 
suggests that these are the causal genetic defects in these two unrelated individuals.  
 
 
DISCUSSION 
Historically the diagnosis of disease is defined by the presenting clinical features but it is becoming 
more apparent that this can give conflicting diagnoses as shown in Tables 1 and 2. Recent advances in 
whole exome and targeted sequencing have enabled a genetic diagnosis to be obtained more readily 
than ever before. This now enables the clinician to consider the possibility of diseases with 
overlapping phenotype based on a genetic result rather than solely relying on the clinical presentation. 
In this report we have elucidated the underlying genetic causal variant(s) in 12 families (comprising 
17 affected individuals) who were given a clinical diagnosis of dyskeratosis congenita. Initially we 
undertook whole exome sequencing on uncharacterised patients who presented with sufficient clinical 
features to be diagnosed as DC. As targeted sequencing methodologies improved, we then chose to 
use this approach as a screening tool to identify patients who had mutations in the known DC and 
bone marrow failure genes (supplementary Table 1). The data reported here represent a sub-set of all 
the cases analysed, where we believe the disease-causing gene has been identified and where the 
identified gene has been previously associated with another genetic syndrome. By using a 
combination of these two strategies we identified disease-causing variants in the genes USB1 (eight 
families, 12 cases), GRHL2 (two families, three cases) and LIG4 (two families, two cases). Clinically 
all patients show a high degree of overlap with the phenotypic profile for DC as described by Dokal et 
al3 and the other diseases with which the disease-causing variants have been associated. This presents 
a problem in defining the disease: is it best to use phenotype or genotype?  
Significantly short telomeres are often used as a biomarker for DC. A telomere length below the 1st 
centile is considered diagnostic for DC but this measurement is not routinely reported in patients with 
other bone marrow failure diseases. Figure 1 shows how telomeres in patients with variants in the 
known telomere genes (DKC1, TERC, TERT and TINF2) are significantly short when compared with 
a control population. Telomere lengths in all affected cases reported here were not significantly short 
when compared with controls regardless of the underlying genetic variant (Figure 1). This measure 
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should perhaps be used where a diagnosis of classical DC is suspected as a screening tool to decide 
the best course of action to determine a genetic diagnosis. Reduced telomere length has also been 
associated with an increased risk of cancer and DC is regarded as a cancer prone syndrome. Patients 
with USB1 mutations tend to have an earlier presentation of myelodysplasia (MDS) than the general 
population as most reports describe disease in children. In this study and in our previous study21 we 
report 6 patients with MDS and 2 with acute myeloid leukemia suggesting there is an increased cancer 
risk despite the patients not having short telomeres. Based on the small number of cases in our series, 
there does not appear to be an increased cancer risk for patients with either GRHL2 or LIG4 
mutations. It is notable however that in the literature LIG4 syndrome is described as a disorder with 
predisposition to leukemia. Although an increased cancer risk is not observed in our families this may 
be due to the small numbers of patients described herein.   
Due to the extensive overlap in clinical features between DC and PN as described in Table 1, telomere 
length seems to be one way of separating these two diagnostic definitions. Given that these cases do 
not have short telomeres but do possess DC features (Table 1) present us with perplexing situation in 
accurately defining these patients. We propose it is timely to combine features of these two entities as 
a new syndrome, “USB1 deficiency syndrome”, characterized by bone marrow failure, abnormal skin 
pigmentation (poikiloderma), nail dystrophy, growth restriction, cancer predisposition and normal 
length telomeres. 
It is also notable that the genes mutated in these overlapping syndromes have similarities with the 
biological functions of the known DC genes (Figure 5). USB1 has a role in snRNA processing, as is 
the case for dyskerin, NHP2 and NOP10.31 It also functions as an exoribonuclease reminiscent to the 
function of PARN that has been recently found to be mutated in both DC and pulmonary fibrosis.32  
Both LIG4 and RTEL1 are involved in the maintenance of genomic stability as they are both involved 
in pathways that repair double strand breaks. LIG4 is an ATP-dependent DNA ligase that joins double 
strand breaks during non-homologous end joining and RTEL1 (a protein that is mutated in a subset of 
DC) is an ATP-dependent DNA helicase, which has an important role in telomere-length regulation. 
Both function via interactions with another shelterin component TRF2 (Telomere repeat binding 
factor 2).33,34 Phenotypically many of the features seen in LIG4/Dubowitz syndrome are also seen in 
DC patients with biallelic RTEL1 mutations (Table 2).7 This supports the idea that mutations in LIG4 
can give rise to phenotype that is reminiscent of DC as caused by a gene that has a known association 
with telomere biology. GRHL2 affects TERT expression by acting on its promoter35, 36 thereby 
providing an important biological link to classical DC. While these proteins do have different 
functions or interactions, we speculate that it is this similarity as suggested in Figure 5 that gives rise 
to the overlapping phenotypes. It is also notable that many of the DC genes have functions other than 
telomere maintenance. It is therefore possible that those overlapping shared functions may also be 
contributing to the similar clinical features observed here.  In the future it will be interesting to 
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determine whether therapeutic agents that work in one disease have a beneficial effect in any of the 
overlapping syndromes. 
 
The findings of this study raise a potential issue as to what constitutes DC. Taking into account the 
clinical features, germline genetic mutation (s) and telomere length we can recognise three categories 
of patients: “Category 1”. Patients with sufficient clinical features (such as abnormal skin 
pigmentation, nail dystrophy, leukoplakia and bone marrow failure) to be labelled as DC, who have a 
germline mutation (s) in a telomere biology gene (such as TERT, TERC, DKC1, TINF2,  RTEL1 and 
so forth) and who have short telomeres (described as being less than 1st centile). “Category 2”. 
Patients with some clinical features of DC (but not sufficient to be classified as DC) who are found to 
have a germline mutation (s) in one of the telomere biology genes and who have short telomeres. 
“Category 3”. Patients with sufficient clinical features of DC but who harbour a germline mutation (s) 
in a non-telomere biology gene (such as USB1, LIG4 and GRHL2) and have normal length telomeres.  
Category 1 patients can be considered to represent “classical or pure DC”. Category 1 and Category 2 
patients can both be considered to represent disorders of telomeres – “telomeropathies”. Category 3 
could be considered as “DC-like” or “DC-overlap”.  
In summary, in nine out of the 12 families highlighted in this study, the biallelic variants identified in 
USB1, GRHL2 and LIG4 have been shown to be pathogenic in previous studies.13,14,20,23,24  In the 
remaining families we have provided strong genetic and in-silico evidence that the identified 
mutations are pathogenic. This study has demonstrated that the pleotropic clinical phenotype of DC 
markedly overlaps with the recognised disease entities LIG4 syndrome, Dubowitz syndrome and PN, 
as well as the recently recognised ECTDS. In doing so it has substantiated the last category as a 
significant disease entity. The marked overlap of features of DC with PN, ECTDS, LIG4 and 
Dubowitz syndromes has important implications for establishing genetic diagnosis when a new 
patient presents in the clinic. Specifically in patients with a clinical diagnosis of DC the genetic 
analysis needs to include GRHL2, LIG4 and USB1 in addition to the classical DC genes. 
 
 
 
All work in this study was conducted with informed, written consent and approval of the local ethics 
committee 
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Table 1: Overlap between DC, PN and patients with homozygous variants in USB1  
Syndrome/ Family 
(OMIM) 
DC (#305000, 
#127500, 
#224230) 
PN 
(#604173) 
Family 1 Family 237 Family 338 Family 4 Family 5 Family 6 Family 7 Family 8 
Consanguinity   Yes   Yes ‡ Yes  Yes 
Country of Origin   Turkey Turkey Turkey Turkey Turkey Australia Afghanistan Afghanistan 
Family history   Yes Yes  Yes     
Age at report 
(years) 
  24,14 12,7,5 7 9, 7 6  10 4 16 
Mutation Various* USB1 p.H179MfsTer86 p.H179MfsTer86 p.H179MfsTer86 p.H179MfsTer86 p.H179MfsTer86 p.Q225Ter p.H208R p.H208R 
Nail dystrophy >60% cases** Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Abnormal skin 
pigmentation 
>60% cases Yes Yes Yes Yes Yes Yes Yes Yes Yes 
BM failure >60% cases Yes Yesa Yesb Yesc Yesd Yese Yesf Yesg Yesh 
Leukoplakia >40% cases  Yes    Yes   Yes 
Developmental 
delay 
>20% cases  Yes Yes  Yes     
Microcephaly >20% cases     Yes     
Growth restriction >20% cases Yes Yes Yes Yes Yes Yes Yes   
Hair loss >20% cases     Yes  Yes   
Pulmonary disease >10% cases Yes Yes  Yes Yes Yes    
Cancer ~10% cases ~10% cases      MDS   
Abnormal 
dentition 
<10% cases Yes Yes Yes    Yes   
Gonadal 
abnormalities 
<10% cases Yes    Yes     
Deafness/ear 
abnormalities 
<10% cases    Yes   Yes   
Eye abnormalities <10% cases       Yes   
Abnormal facies <10% cases Yes  Yes Yes   Yes  Yes 
Skeletal 
abnormalities 
<10% cases       Yes   
Immune deficiency <10% cases  Yes    Yes  Yes Yes 
Short telomeres <1st centile Unknown Normal Normal Normal Normal Normal Normal Normal Normal 
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All clinical features reported within a family are detailed. DC-Dyskeratosis congenita; PN-
poikiloderma with neutropenia; * Mutations identified in CTC1, DKC1, NHP2, NOP10, PARN, 
RTEL1, TERC, TERT, TINF2, TPP1 and WRAP53; ** as calculated from the index cases of the 1st 
400 families included in the DCR, London; †Term used to cover short stature, intra uterine growth 
restriction and low birth weight; ‡Parents reported as being from the same village but no statement of 
consanguinity. The blood counts for the index case at presentation are as follows: a-hemoglobin 
106g/l, leucocytes 2.3x109/l, neutrophils 0.3x109/l,  platelets 246x109/l and bone marrow showed 
decreased cellularity; b-hemoglobin 125g/l, leucocytes 3.2x109/l, neutrophils 0.1x109/l, platelets 
311x109/l and bone marrow showed decreased cellularity with approximately 10% blasts; c-
hemoglobin 113g/l, leucocytes 3.2x109/l, neutrophils 0.8x109/l platelets 308x109/l; d-hemoglobin 
115g/l, leucocytes 3.4x109/l, neutrophils 0.8x109/l, platelets 138x109/l; e-hemoglobin 121g/l, 
leucocytes 3.68x109/l, neutrophils 0.7x109/l, platelets 269x109/l; f-hemoglobin 70g/l, leucocytes 
2.1x109/l, neutrophils 1.1x109/l, platelets 5x109/l and bone marrow showed increased cellularity, 
decreased magakaryocytes, dysmyelopoiesis with nuclear changes and abnormal granularity; g- 
hemoglobin 115g/l, leucocytes 4.5x109/l, neutrophils 0.9x109/l, platelets 204x109/l; h-hemoglobin 
114g/l, leucocytes 1.7x109/l, neutrophils 0.8x109/l, platelets 112x109/l. MDS- myelodysplastic 
syndrome.
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Table 2: Clinical overlap between the different genetic syndromes and the families with biallelic variants identified in this study  
Syndrome/Family 
(OMIM reference) 
DC (#305000, 
#127500, #224230) 
ECTDS 
(#616029) 
Family 9 Family 1025 LIG4 syndrome 
(#606593) 
Dubowitz syndrome 
(#223370) 
Family 11 
 
Family 12 
 
Consanguinity   Yes Yes     
Country of origin   Kuwait Turkey   Guadeloupe UK 
Family history   Yes      
Age at report (years)   10, 5 27   5 5 
Mutated gene (variant 
identified) 
Various* GRHL2 (p.Y398H, 
p.I482K) 
GRHL2 
(p.I482K) 
GRHL2 
(p.P405T) 
LIG4 (various) LIG4 (p.R814Ter, 
p.S205LfsTer29) 
LIG4 
(p.R814Ter, 
p.K424RfsTer20) 
LIG4 
(p.R814Ter, 
p.K424RfsTer20) 
Nail dystrophy >60% cases** Yes Yes Yes     
Abnormal skin 
pigmentation 
>60% cases Yes Yes Yes Yes  1 café au lait spot  
BM failure >60% cases  Noa Yesb Yes Yes Yesc Yesd 
Leukoplakia >40% cases Yes Yes Yes     
Developmental delay >20% cases    Yes Yes   
Microcephaly >20% cases    Yes Yes Yes Yes 
Growth restriction† >20% cases Yes Yes Yes Yes Yes Yes Dwarfism 
Abnormal dentition <10% cases Yes Yes Yes  Yes   
Oesophageal stricture <10% cases Yes       
Gonadal abnormalities <10% cases   Yes Yes Yes   
Ataxia <10% cases        
Immune deficiency <10% cases    Yes  Yes Yes 
Deafness/ear 
abnormalities 
<10% cases Yes       
Kidney abnormalities <10% cases  Recurrent 
infections 
Renal 
agenesis 
    
Abnormal facies <10% cases    Yes Yes Yes  
Short telomeres <1st centile Unknown Normal Normal Unknown <1st centilee Normal Normal 
All clinical features reported within a family are detailed. ECTDS – Ectodermal dysplasia/short stature syndrome. * Mutations identified in CTC1, DKC1, NHP2, NOP10, 
PARN, RTEL1, TERC, TERT, TINF2,  TPP1 and WRAP53;** as calculated from the index cases of the 1st 400 families in the DCR, London; †Term used to cover short 
stature, intra uterine growth restriction and low birth weight. The blood counts for the index case at presentation are as follows: a - hemoglobin 141g/l, leucocytes 
7.2x109/l, neutrophils 4.4x109/l, platelets 307x109/l (normal blood counts); b-hemoglobin 89g/l, leucocytes 4.9x109/l, platelets 216x109/l and bone marrow showed reduced 
cellularity with megaloblastic changes; c-hemoglobin 96g/l, neutrophils 0.5x109/l, platelets 20x109/l and bone marrow  showed reduced cellularity and reduced 
megakaryocytes; d-pancytopenia with B-lymphopenia and bone marrow showed reduced cellularity. e- reported in 3 patients only 
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Figure Legends 
Figure 1: Telomere lengths in patients with GRHL2, LIG4 and USB1 mutations are not short 
Relative T/S ratios are within the normal range. Open circles – controls (n=130); green diamonds – 
patients with biallelic USB1 variants (n=12), blue triangles – patients with homozygous GRHL2 
variants (n=2); Inverted red triangles – patients with compound heterozygous LIG4 variants (n=2). 
For comparison short telomeres are seen in patients with mutations in the known telomere associated 
genes DKC1 (n=50, open squares), TERC (n=66, open triangles), TERT (n=36, open inverted 
triangles) and TINF2 (n=33, open diamonds). Black line represents the median for each data set.  
 
Figure 2: Identification and segregation of disease-causing variants in USB1  
A) The c.531delA variant is identified in five families with a DC phenotype. Representative 
sequencing traces are shown for the wild type (+/+), heterozygous (+/-) and homozygous (-/-) 
forms of the mutation. 
B) Family tree and sequence traces of c.673C>T variant seen in Family 6. A representative 
heterozygous trace and the homozygous trace are shown.  
C) Family tree and sequence traces of the novel c.623A>G homozygous variant (G/G) as seen in 
Family 7 and 8. A representative wild type (A/A) trace is also shown. NA – sample not available. 
D) Protein crystal structure of human USB1 (PDB id: 4W7H) depicted in ribbon form indicating the 
both transit and terminal lobes indicated in green α helices. The position of identified residues 
mutated in USB1 deficiency patients is indicated as stick model in blue.  
E and F) In silico modelling of truncation mutations reveals loss several α helices and β sheets in both 
transit and terminal lobes of USB1 secondary structure. 
G and H) The invariant H-x-S motif in the active site is indicated as stick model. The missense change 
Histidine to Arginine at 208 position (red) introduces an extra hydrogen bond (dotted line black 
indicated by arrows), with Ser210 (blue), which in turn might cause aberrant oligoadenylation of 
RNA substrate. 
 
Figure 3: Similar clinical presentation is observed between DC and PN highlighting the marked 
overlap between these two syndromes  
Panels A, D, G are from a male patient with p.Ala353Val DKC1mutation, panels B, E and H are from 
a male patient with the homozygous USB1 p.His127MetfsTer86 mutation and panels C, F I are from a 
child with the homozygous USB1 p.His208Arg mutation . Panels A-C show similar patterns of 
reticular pigmentation on the legs. Panels D-F show nail dystrophy on the toes. Panels G and H show 
reticular pigmentation on the trunk and panel I shows pigmentation on the arm along with nail 
dystrophy on the figures. It is notable that the mucocutaneous features of the patient with USB1 
p.His179MetfsTer86 mutation appear more like those of the patient with DKC1 p.Ala353Val 
mutation than the one with the USB1 p.His208Arg mutation. 
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Figure 4: Identification of disease-causing variants in two different genes in patients with 
clinical features of DC 
A) Segregation and sequence traces for the homozygous GRHL2 variants identified in Families 9 and 
10. Representative heterozygous and homozygous traces are shown for both variants. Schematic 
representation of the protein shows the identified domains and the location of the variants. Red 
arrow highlights the variant identified in this study. Black arrow highlights a variant identified in 
previous study. Green arrow highlights the variant observed in both this and previous study.NA-
sample not available.  
B) Segregation and sequence traces for the compound heterozygous LIG4 variants identified in 
Families 11 and 12. A representative wild type and heterozygous trace is shown for each. The 
nucleotides deleted are indicated by a line above the corresponding bases on the wild type (+/+) 
trace. Schematic representation of the protein showing the precise location of variants in different 
domains. Black arrows highlight variants identified in previous studies. Green arrows highlight 
variants observed in both this and previous studies.  
 
Figure 5: Biological overlap of classical DC proteins (TERT, DKC1, NOP10, NHP2, PARN and 
RTEL1) and those (GRHL2, USB1 and LIG4) mutated in patients in this study 
Proteins with similar functions are grouped together. The schematic shows that GRHL2 can be 
grouped broadly with the molecules which have role in telomerase expression, USB1 with small 
nuclear ribonucleoprotein (snRNP) processing and LIG4 with genomic stability. Previous studies 
have shown that biallelic mutations in GRHL2, USB1 and LIG4 are associated with ectodermal 
dysplasia, poikiloderma with neutropenia (or USB1 deficiency syndrome) and Lig4/Dubowitz 
syndrome, respectively. Mutations in DKC1, NHP2, NOP10, PARN and RTEL1 have been linked to 
dyskeratosis congenita.  
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